All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Nicolaus Kröger, University Medical Center Hamburg-Eppendorf, Hamburg, DE, about allogeneic stem cell transplantation (allo-SCT). We asked, At what point should allo-SCT (or auto-allo-SCT) be considered for patients with MM?
At what point should allo-SCT (or auto-allo-SCT) be considered for patients with MM?
Unlike autologous-SCT, allo-SCT has not become a standard of care for the treatment of MM. However, long term data exist showing that allo-SCT has the potential to be curative. At the same time, SCT-associated morbidity and mortality can be high, highlighting the importance of patient selection. Nicolaus Kröger discusses the results from several studies comparing auto-SCT with allo-SCT.
Subscribe to get the best content related to multiple myeloma delivered to your inbox